Fig. 4: Capmatinib blocks tumor formation and malignant conversion in Tpl2−/− mice subjected to two-stage chemical carcinogenesis. | Oncogenesis

Fig. 4: Capmatinib blocks tumor formation and malignant conversion in Tpl2−/− mice subjected to two-stage chemical carcinogenesis.

From: Inhibition of HGF/MET signaling decreases overall tumor burden and blocks malignant conversion in Tpl2-related skin cancer

Fig. 4

Mice were treated once with 100μg DMBA/200μL acetone. Promotion with 10μg/200μL TPA was started 1 week later and continued for 20 weeks. At the time of promotion half of each genotype received 44 mg/kg capmatinib in their diet. Tumors were measured weekly. The percentage of tumor-bearing mice (a) and the number of tumors per mouse (b) are plotted vs. time for each group. One-proportion confidence intervals (a) and SEM (b) were used to generate error bars. Significant differences between curves appeared by week 20 and remained significant until the termination of the study. Significant differences were determined by two-way ANOVA (p < 0.001). c The percentage of mice receiving DMBA only (no promotion with TPA) are plotted vs. time and significant by week 20 (p < 0.05) and highly significant (p < 0.0001) by week 40. Error bars were calculated using one-proportion confidence intervals. d Summary of histological examination from the two-stage carcinogenesis experiment. e Tumor number and responsivity to capmatinib in males vs. females. f Photograph of representative DMBA/TPA mice

Back to article page